Elsevier

Journal of Hepatology

Volume 72, Issue 6, June 2020, Pages 1196-1209
Journal of Hepatology

Review
Update on NAFLD genetics: From new variants to the clinic

https://doi.org/10.1016/j.jhep.2020.02.020Get rights and content

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver diseases in high-income countries and the burden of NAFLD is increasing at an alarming rate. The risk of developing NAFLD and related complications is highly variable among individuals and is determined by environmental and genetic factors. Genome-wide association studies have uncovered robust and reproducible associations between variations in genes such as PNPLA3, TM6SF2, MBOAT7, GCKR, HSD17B13 and the natural history of NAFLD. These findings have provided compelling new insights into the biology of NAFLD and highlighted potentially attractive pharmaceutical targets. More recently the development of polygenic risk scores, which have shown promising results for the clinical risk prediction of other complex traits (such as cardiovascular disease and breast cancer), have provided new impetus for the clinical validation of genetic variants in NAFLD risk stratification. Herein, we review current knowledge on the genetic architecture of NAFLD, including gene-environment interactions, and discuss the implications for disease pathobiology, drug discovery and risk prediction. We particularly focus on the potential clinical translation of recent genetic advances, discussing methodological hurdles that must be overcome before these discoveries can be implemented in everyday practice.

Introduction

Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver disease in high-income countries, affecting more than 25% of the population.1 The inflammatory form of this condition, namely non-alcoholic steatohepatitis (NASH), is responsible for an increasing proportion of cases of cirrhosis and hepatocellular carcinoma (HCC).2,3 As for other complex traits (e.g. circulating lipids or cardiovascular diseases), the risk of developing NAFLD and NASH varies among individuals; it is ultimately determined by the combination of environmental factors, such as adiposity or the presence of type 2 diabetes (T2D), and inherited genetic variations.

Historically, genetic susceptibility to NAFLD has been evaluated using candidate gene studies – a study design evaluating the association of variants in a given gene and a phenotype of interest. However, most candidate gene studies have only identified and validated a handful of loci associated with the risk of NAFLD prevalence or progression. This can be explained by the limited number of genes selected a priori based on their plausible biological relevance, but also by various methodological drawbacks (e.g. limited statistical power).4 Conversely, genome-wide association studies (GWAS) test the association of millions of variants throughout the genome in an unbiased fashion. GWAS can be performed using various technologies, like single nucleotide polymorphism (SNP) arrays followed by imputation, a statistical method for inferring genotypes that are not directly measured using large reference panels (e.g. 1000G or the Haplotype Reference Consortium).5,6 More recently, next-generation sequencing approaches have been implemented, including whole-exome sequencing (WES), targeting the fraction of the genome that encodes proteins, or whole-genome sequencing (WGS). GWAS have identified robust and reproducible associations linked with the natural history of NAFLD, including variants in the patatin-like phospholipase domain-containing 3 (PNPLA3), the transmembrane 6 superfamily member 2 (TM6SF2) and more recently in the 17-beta hydroxysteroid dehydrogenase 13 (HSD17B13) genes.7 GWAS have uncovered novel NAFLD susceptibility genes and biological pathways and fostered improved understanding of NAFLD pathophysiology.

Herein, we provide an update on our current knowledge of NAFLD genetics and discuss the benefits and limitations of recent GWAS findings including biological understanding, risk prediction and drug development. Based on the available evidence, we propose suggestions for interpretation, and design of new studies in the field. We will frequently use the more general term fatty liver disease (FLD), as at risk alcohol intake was not an exclusion criterium in most studies, and it is always difficult to differentiate the role of alcohol and metabolic risk factors.8 Furthermore, genetic studies have highlighted shared inherited determinants of metabolic and alcohol-related FLD.9

Key point

Growing evidence has shown that the risk of NAFLD occurrence and progression varies among individuals and has highlighted the role of inherited genetic variants.

Section snippets

Heritability of NAFLD

Heritability is defined as the proportion of phenotypic variation in a trait that is due to genetic variation.10 Unlike monogenic diseases, such as hereditary haemochromatosis and Wilson's disease, the heritability of complex traits involves thousands of common genetic variants (minor-allele frequency [MAF] ≥5%) distributed throughout the genome, which are usually characterised by small effect sizes (e.g. relative risks or odds ratios [ORs]).11

A large fraction of hepatic fat and FLD variability

Genetic association findings in NAFLD are dependent on the study sample size

Recognition of the validity of GWAS for providing new insights into complex traits, as recently demonstrated for NAFLD, relies on the high reproducibility and robustness of their findings. However, this success comes at the cost of a stringent statistical significance threshold (p <5×10−8) used in most GWAS to correct for the burden of multiple testing, as millions of SNPs throughout the genome are assessed.83 The sample size required to detect a given genetic variant with suitable statistical

A roadmap to clinical translation

Based on the evidence reviewed in this manuscript, we propose a checklist for genetic studies aimed at further advancing the field of NAFLD, to ensure methodological robustness, reproducibility, and clinical relevance (Table S1). This is not an alternative to the STrengthening the REporting of Genetic Association Studies (STREGA) reporting guidelines,97 which should be taken into consideration, but provides specific suggestions relevant for NAFLD.

Conclusions and practical recommendations

Specific genetic risk variants have now been robustly confirmed to exert a large impact on NAFLD, with an effect size comparable and synergic to that of the main metabolic risk factors, namely obesity and type 2 diabetes. This risk increase extends to the development and progression of the full spectrum of NAFLD, extending to liver-related and overall mortality. Furthermore, genetic risk variants may be able to profile subsets of patients with different pathophysiology and response to

Financial support

LV was supported by MyFirst Grant AIRC n.16888, Ricerca Finalizzata Ministero della Salute RF-2016-02364358, Ricerca corrente Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Fondazione Sviluppo Ca' Granda for the project Liver-Bible (PR-0361); the European Union (EU) Programme Horizon 2020 (under grant agreement No. 777377) for the project LITMUS-“Liver Investigation: Testing Marker Utility in Steatohepatitis”.

ET was supported by a Marie Skłodowska-Curie Individual Fellowship, the

Authors' contribution

Authors contributed equally to the design, conceptualisation, writing of the manuscript, LV supervised the process.

Conflict of interest

LV reports having received speaking fees from: MSD, Gilead, AlfaSigma, AbbVie; consulting fees from: Gilead, Pfizer, Astra Zeneca, Novo Nordisk, Intercept pharmaceuticals, Diatech Pharmacogenetics; unrestricted research grants from: Gilead.

ET received unrestricted research grant from Gilead.

Please refer to the accompanying ICMJE disclosure forms for further details.

References (144)

  • B. Cai et al.

    Macrophage MerTK promotes liver fibrosis in nonalcoholic steatohepatitis

    Cell Metab

    (2020)
  • P. Dongiovanni et al.

    PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients

    J Lipid Res

    (2019)
  • L. Valenti et al.

    HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease

    Gastroenterology

    (2010)
  • L. Valenti et al.

    Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease

    J Hepatol

    (2010)
  • A. Al-Serri et al.

    The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies

    J Hepatol

    (2012)
  • S. Petta et al.

    MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease

    J Hepatol

    (2016)
  • M.A. Mitsche et al.

    Patatin-like phospholipase domain-containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets

    J Biol Chem

    (2018)
  • L. Youssefian et al.

    Inherited non-alcoholic fatty liver disease and dyslipidemia due to monoallelic ABHD5 mutations

    J Hepatol

    (2019)
  • M. Pericleous et al.

    Wolman's disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency

    Lancet Gastroenterol Hepatol

    (2017)
  • P.K. Luukkonen et al.

    The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans

    J Hepatol

    (2016)
  • M. Meroni et al.

    Down-regulation of hepatic MBOAT7 by hyperinsulinemia favors steatosis development

    J Hepatol

    (2018)
  • P.K. Luukkonen et al.

    Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD

    J Hepatol

    (2017)
  • D.S. Kim et al.

    Novel association of TM6SF2 rs58542926 genotype with increased serum tyrosine levels and decreased apolipoprotein B-100 particles in Finns

    J Lipid Res

    (2017)
  • M. Di Filippo et al.

    Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia

    J Hepatol

    (2014)
  • A. Mondul et al.

    PNPLA3 1148M variant influences circulating retinol in adults with nonalcoholic fatty liver disease or obesity

    J Nutr

    (2015)
  • N.R. Wray et al.

    Common disease is more complex than implied by the core gene omnigenic model

    Cell

    (2018)
  • Z. Younossi et al.

    Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

    Nat Rev Gastroenterol Hepatol

    (2018)
  • K.E. Lohmueller et al.

    Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease

    Nat Genet

    (2003)
  • C. Genomes Project et al.

    A global reference for human genetic variation

    Nature

    (2015)
  • S. McCarthy et al.

    A reference panel of 64,976 haplotypes for genotype imputation

    Nat Genet

    (2016)
  • A.E. Taliento et al.

    Novel insights into the genetic landscape of nonalcoholic fatty liver disease

    Int J Environ Res Public Health

    (2019)
  • P.M. Visscher et al.

    Heritability in the genomics era–concepts and misconceptions

    Nat Rev Genet

    (2008)
  • P. Dongiovanni et al.

    Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver

    J Intern Med

    (2018)
  • S. Pelusi et al.

    Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease

    Liver Int

    (2019)
  • R. Guerrero et al.

    Ethnic differences in hepatic steatosis: an insulin resistance paradox?

    Hepatology

    (2009)
  • C. Caussy et al.

    Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis

    J Clin Invest

    (2017)
  • M.T. Long et al.

    Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring

    Liver Int

    (2019)
  • S. Romeo et al.

    Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

    Nat Genet

    (2008)
  • E.K. Speliotes et al.

    Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits

    PLoS Genet

    (2011)
  • J. Kozlitina et al.

    Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease

    Nat Genet

    (2014)
  • N.S. Abul-Husn et al.

    A protein-truncating HSD17B13 variant and protection from chronic liver disease

    N Engl J Med

    (2018)
  • P. Dongiovanni et al.

    PNPLA3 I148M polymorphism and progressive liver disease

    World J Gastroenterol

    (2013)
  • S. Sookoian et al.

    Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease

    Hepatology

    (2011)
  • L. Valenti et al.

    Homozygosity for the PNPLA3 / adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease

    Hepatology

    (2010)
  • Y.L. Liu et al.

    Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma

    J Hepatol

    (2013)
  • B. Donati et al.

    MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals

    Sci Rep

    (2017)
  • S. Buch et al.

    A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis

    Nat Genet

    (2015)
  • L. Valenti et al.

    Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C

    Hepatology

    (2011)
  • M. Vigano et al.

    Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B

    Hepatology

    (2013)
  • L. Valenti et al.

    Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis

    World J Gastroenterol

    (2012)
  • Cited by (223)

    View all citing articles on Scopus

    Author names in bold designate shared co-first authors

    View full text